This announcement is a separate document:
アステラス製薬：VYLOY（ゾルベツキシマブ） 局所進行性または転移性胃腺がんおよび 食道胃接合部腺がんに対する化学療法との併用として 欧州で承認取得
Astellas Pharma: VYLOY (zolbetuximab) approved in Europe for use in combination with chemotherapy for locally advanced or metastatic gastric adenocarcinoma and esophagogastric junction adenocarcinoma
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.